Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drop biologic suffixes IGBA urges US FDA

Executive Summary

Additional identifiers such as suffixes to international non-proprietary names (INNs) are not needed for successful traceability and identification of biological drugs, the International Generic and Biosimilar Medicines Association (IGBA) argues in an updated position. “No data exists to demonstrate that added non-memorable suffixes in the US will improve the US pharmacovigilance system,” the international trade body has stressed ahead of a US Food and Drug Administration (FDA) public hearing on “facilitating price competition and innovation in the biological products marketplace” to be held on 4 September (Generics bulletin, 3 August 2018, page 9).

You may also be interested in...



US Must Rethink Biologic Naming Suffix, Says IGBA

In the wake of a decision by Health Canada not to implement a suffix to non-proprietary names to distinguish biosimilars from their branded counterparts, the IGBA has urged the FDA to reconsider the US approach.

US Must Rethink Biologic Naming Suffix, Says IGBA

In the wake of a decision by Health Canada not to implement a suffix to non-proprietary names to distinguish biosimilars from their branded counterparts, the IGBA has urged the FDA to reconsider the US approach.

Canadian Decision On Biological Names Leaves US As The Outlier

Health Canada’s decision to not add a suffix to non-proprietary names for biologics, including biosimilars, has left the US as the only major territory to operate such a convention. The move has been welcomed by the Canadian generics industry.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB001121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel